{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:38:25Z","timestamp":1787027905269,"version":"build-2736575974"},"reference-count":28,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"MSD Portugal","award":["NIS008968"],"award-info":[{"award-number":["NIS008968"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Recurrent or metastatic head and neck squamous cell carcinoma (R\/M HNSCC) is a challenging disease, requiring personalized management by a multidisciplinary team. The aim of this retrospective multicentric study was to characterize real-world healthcare resource use and patient care for R\/M HNSCC in Portugal during the first year after diagnosis. A total of 377 patients ineligible for curative treatment were included, mostly male (92.8%), aged 50\u201369 years (74.5%), with heavy alcohol (72.7%) or smoking habits (89.3%). Oropharynx (33.2%) and oral cavity (28.7%) were primary tumor locations, with lung metastases being the most common (61.4%). Eligible patients for systemic treatment with palliative intent (80.6%) received up to four treatment lines, with varied regimens. Platinum-based combination chemotherapy dominated first-line treatment (&gt;70%), while single-agent chemotherapy and anti-PD1 immunotherapy were prevalent in later lines. Treatment approaches were uniform across disease stages and primary tumor locations but varied geographically. Treated patients received more multidisciplinary support than those who were ineligible. This study provides the first Portuguese real-world description of R\/M HNSCC patient characteristics, treatment patterns, and supportive care during the year after diagnosis, highlighting population heterogeneity and aiming to improve patient management.<\/jats:p>","DOI":"10.3390\/curroncol31080318","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T14:39:08Z","timestamp":1722004748000},"page":"4270-4283","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-World Healthcare Resource Use Associated with Recurrent or Metastatic Head and Neck Cancer Patients Care in Portugal\u2014TRACE Study"],"prefix":"10.3390","volume":"31","author":[{"given":"Maria Margarida","family":"Teixeira","sequence":"first","affiliation":[{"name":"Instituto Portugu\u00eas de Oncologia de Coimbra Francisco Gentil, 3000-075 Coimbra, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Dias","sequence":"additional","affiliation":[{"name":"Instituto Portugu\u00eas de Oncologia do Porto Francisco Gentil, 4200-072 Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4807-1505","authenticated-orcid":false,"given":"Teresa","family":"Andr\u00e9","sequence":"additional","affiliation":[{"name":"Hospital Dr. N\u00e9lio Mendon\u00e7a, 9000-177 Funchal, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7064-9639","authenticated-orcid":false,"given":"Ana","family":"Joaquim","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade de Gaia\/Espinho, 4434-502 Vila Nova de Gaia, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0301-7257","authenticated-orcid":false,"given":"Ricardo","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade de Braga, 4710-243 Braga, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Magalh\u00e3es","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade do Algarve, 8000-386 Faro, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Marreiros","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade de Almada-Seixal, 2805-267 Almada, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonor","family":"Pinto","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade de Coimbra, 3004-561 Coimbra, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonor","family":"Ribeiro","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade de Santa Maria, 1649-035 Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mafalda","family":"Nogueira","sequence":"additional","affiliation":[{"name":"MSD Portugal, 2770-192 Pa\u00e7o de Arcos, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catarina","family":"Morais","sequence":"additional","affiliation":[{"name":"MSD Portugal, 2770-192 Pa\u00e7o de Arcos, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.critrevonc.2019.05.002","article-title":"Target therapies in recurrent or metastatic head and neck cancer: State of the art and novel perspectives","volume":"139","author":"Muratori","year":"2019","journal-title":"A systematic review. Crit. Rev. Oncol. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.clinthera.2018.02.010","article-title":"Patient Characteristics and Costs in Recurrent or Refractory Head and Neck Cancer: Retrospective Analysis of a Community Oncology Database","volume":"40","author":"Fisher","year":"2018","journal-title":"Clin. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s40273-014-0169-3","article-title":"The economic burden of head and neck cancer: A systematic literature review","volume":"32","author":"Wissinger","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1158\/1055-9965.EPI-08-0347","article-title":"Interaction between tobacco and alcohol use and the risk of head and neck cancer: Pooled analysis in the International Head and Neck Cancer Epidemiology Consortium","volume":"18","author":"Hashibe","year":"2009","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41415-022-5166-x","article-title":"Reviewing the epidemiology of head and neck cancer: Definitions, trends and risk factors","volume":"233","author":"Gormley","year":"2022","journal-title":"Br. Dent. J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"873","DOI":"10.6004\/jnccn.2020.0031","article-title":"Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Pfister","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.oraloncology.2017.04.002","article-title":"Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy","volume":"69","author":"Siano","year":"2017","journal-title":"Oral Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1200\/JCO.21.02198","article-title":"Pembrolizumab Alone or With Chemotherapy for Recurrent\/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score","volume":"40","author":"Burtness","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/MOO.0000000000000448","article-title":"Immunotherapy for recurrent\/metastatic head and neck cancer","volume":"26","author":"Alfieri","year":"2018","journal-title":"Curr. Opin. Otolaryngol. Head Neck Surg."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): A randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/13696998.2019.1676760","article-title":"Real-world treatment patterns, cost of care and effectiveness of therapies for patients with squamous cell carcinoma of head and neck pre and post approval of immuno-oncology agents","volume":"23","author":"Abraham","year":"2020","journal-title":"J. Med. Econ."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.annonc.2020.07.011","article-title":"Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Machiels","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s41687-018-0060-7","article-title":"Patients\u2019 experience of recurrent\/metastatic head and neck squamous cell carcinoma and their perspective on the EORTC QLQ-C30 and QLQ-H&N35 questionnaires: A qualitative study","volume":"2","author":"Degboe","year":"2017","journal-title":"J. Patient Rep. Outcomes"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e12862","DOI":"10.1111\/ecc.12862","article-title":"Treatment patterns and health care resource use in patients receiving multiple lines of therapy for metastatic squamous cell carcinoma of the head and neck in the United Kingdom","volume":"27","author":"La","year":"2018","journal-title":"Eur. J. Cancer Care"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"739","DOI":"10.2217\/fon-2018-0572","article-title":"Treatment patterns and outcomes among patients with recurrent\/metastatic squamous cell carcinoma of the head and neck","volume":"15","author":"Nadler","year":"2019","journal-title":"Future Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s00405-015-3495-y","article-title":"Treatments and costs for recurrent and\/or metastatic squamous cell carcinoma of the head and neck in the Netherlands","volume":"273","author":"Buter","year":"2016","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3904\/kjim.2020.636","article-title":"Characteristics and treatment patterns in older patients with locally advanced head and neck cancer (KCSG HN13-01)","volume":"37","author":"Kang","year":"2022","journal-title":"Korean J. Intern. Med."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Singh, P., Bennett, B., Bailey, T., Taylor-Stokes, G., Rajkovic, I., Contente, M., Curtis, S., and Curtis, C. (2021). Real-world study of the impact of recurrent\/metastatic squamous cell carcinoma of the head and neck (R\/M SCCHN) on quality of life and productivity in Europe. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08557-2"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the Tidyverse","volume":"4","author":"Wickham","year":"2019","journal-title":"J. Open Source Softw."},{"key":"ref_23","unstructured":"Team, R.D.C. (2010). R: A Language and Environment for Statistical Computing, R Core Team."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa071028","article-title":"Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer","volume":"357","author":"Vermorken","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/ijc.32164","article-title":"Human papillomavirus and p16 immunostaining, prevalence and prognosis of squamous carcinoma of unknown primary in the head and neck region","volume":"145","author":"Ren","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/cncr.32652","article-title":"Short-term mortality risks among patients with oropharynx cancer by human papillomavirus status","volume":"126","author":"Fullerton","year":"2020","journal-title":"Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"761","DOI":"10.6004\/jnccn.2017.0101","article-title":"NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017","volume":"15","author":"Adelstein","year":"2017","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"479","DOI":"10.6004\/jnccn.2018.0026","article-title":"NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018","volume":"16","author":"Colevas","year":"2018","journal-title":"J. Natl. Compr. Cancer Netw."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/8\/318\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:24:39Z","timestamp":1760109879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/8\/318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,26]]},"references-count":28,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["curroncol31080318"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31080318","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,26]]}}}